Unveiling the Potential Drug Target and Biomarker BICDL1: Coiled-coil Domain-Containing Protein 64A

Target Name: BICDL1

NCBI ID: G92558

BICDL1

Unveiling the Potential Drug Target and Biomarker BICDL1: Coiled-coil Domain-Containing Protein 64A

Introduction

Protein 64A, also known as BICDL1 (Coiled-coil domain-containing protein 64A), is a key regulator of the growth, development, and survival of various tissues in the human body. This protein is expressed in nearly all human tissues and has been implicated in numerous biological processes, including cell division, apoptosis, angiogenesis, and inflammation. Although the primary function of BICDL1 is not well understood, its unique coiled-coil domain has led to the speculation that it may serve as a drug target or biomarker. In this article, we will explore the potential drug target and biomarker properties of BICDL1 and its implications for future research.

Drug Target Potential

The drug discovery process is an iterative process that targets potential drug molecules based on their ability to interact with specific protein targets. BICDL1, with its unique coiled-coil domain, has the potential to serve as a drug target due to its involvement in various cellular processes that are associated with the development of diseases.

One of the key functions of BICDL1 is its role in cell division. BICDL1 is known to be involved in the regulation of cell cycle progression, which is critical for the development and progression of cancer. Several studies have shown that BICDL1 plays a negative role in the regulation of cell division and has been implicated in the development of various types of cancer, including breast, ovarian, and prostate cancer. Therefore, targeting BICDL1 with drugs that can inhibit its function may be an effective way to develop new cancer therapies.

Another potential drug target for BICDL1 is its role in apoptosis, which is a natural process that helps regulate cell death. BICDL1 has been shown to be involved in the regulation of apoptosis, which is critical for the elimination of damaged or dysfunctional cells. The deregulation of apoptosis has been implicated in the development of various diseases, including neurodegenerative disorders, cancer, and cardiovascular diseases. Therefore, targeting BICDL1 with drugs that can promote apoptosis may be an effective way to develop new therapies for these diseases.

Biomarker Potential

The diagnosis and prognosis of many diseases are based on the measurement of specific biomarkers, which are indicators of the presence or absence of a particular disease. BICDL1 has the potential to serve as a biomarker due to its unique expression patterns and involvement in various biological processes.

One of the key biomarkers associated with BICDL1 is its expression level. Studies have shown that BICDL1 is highly expressed in various tissues, including cancer, and its expression level can be used as a marker for disease progression. Therefore, targeting BICDL1 with drugs that can reduce its expression may be an effective way to develop new therapies for cancer.

Another biomarker associated with BICDL1 is its role in inflammation. BICDL1 has been shown to be involved in the regulation of inflammation, which is a critical aspect of many diseases, including cancer. Therefore, targeting BICDL1 with drugs that can inhibit its function in inflammation may be an effective way to develop new therapies for these diseases.

Conclusion

In conclusion, BICDL1 has the potential to serve as a drug target and biomarker due to its involvement in various biological processes that are associated with the development of diseases. The unique coiled-coil domain of BICDL1 makes it an attractive target for drug discovery, and its involvement in cell division, apoptosis, and inflammation make it a promising biomarker for disease diagnosis and prognosis. Further research is needed to fully understand the

Protein Name: BICD Family Like Cargo Adaptor 1

Functions: Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track). Predominantly recruits 2 dyneins, which increases both the force and speed of the microtubule motor. Component of secretory vesicle machinery in developing neurons that acts as a regulator of neurite outgrowth. Regulates the secretory vesicle transport by controlling the accumulation of Rab6-containing secretory vesicles in the pericentrosomal region restricting anterograde secretory transport during the early phase of neuronal differentiation, thereby inhibiting neuritogenesis

The "BICDL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BICDL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets